Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07YHY
|
|||
| Former ID |
DIB013013
|
|||
| Drug Name |
CR-2093
|
|||
| Synonyms |
CR-2093; CR 2093; 136374-73-7; AC1L303W; 4-(3-Chlorobenzamido)-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; (R)-4-(3-Chlorobenzoylamino)-5-oxo-5-(3,3-dimethylbutylamino)valeric acid; (4R)-4-[(3-chlorobenzoyl)amino]-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; Pentanoic acid, 4-((3-chlorobenzoyl)amino)-5-((3,3-dimethylbutyl)amino)-5-oxo-, (R)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Intestine cancer [ICD-11: 2C0Z] | Discontinued in Phase 1 | [1] | |
| Company |
Rotta Research Lab SpA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H25ClN2O4
|
|||
| Canonical SMILES |
CC(C)(C)CCNC(=O)C(CCC(=O)O)NC(=O)C1=CC(=CC=C1)Cl
|
|||
| InChI |
1S/C18H25ClN2O4/c1-18(2,3)9-10-20-17(25)14(7-8-15(22)23)21-16(24)12-5-4-6-13(19)11-12/h4-6,11,14H,7-10H2,1-3H3,(H,20,25)(H,21,24)(H,22,23)/t14-/m1/s1
|
|||
| InChIKey |
VUYSXYHJEIPUTG-CQSZACIVSA-N
|
|||
| CAS Number |
CAS 136374-73-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastrin/cholecystokinin type B receptor (CCKBR) | Target Info | Modulator | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gastric acid secretion | ||||
| Panther Pathway | CCKR signaling map ST | |||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001442) | |||
| REF 2 | Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.